Top Markets
Coin of the day
Immunotech Biopharm Ltd Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

6978
Rangering i aksjer #27877
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in... Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Aksjekurs
$0.04861197
Markedsverdi
$30.02M
Endring (1 dag)
0.00%
Endring (1 år)
-91.39%
Land
CN
Handel Immunotech Biopharm Ltd (6978)

Kategori

P/S-forhold for Immunotech Biopharm Ltd (6978)
P/S-forhold per 2026 TTM: 0
Ifølge Immunotech Biopharm Ltd sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Immunotech Biopharm Ltd fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
11.28 -
US
10.13 -
NL
2.95 -
AU
- -
CH